科研动态PubMed 摘要

阿司匹林使用对心脏移植后死亡率和心脏移植物血管病的影响:一项系统综述与荟萃分析。

PubMed 学科轮询 · 2026-01-01

完整摘要 · 中文译文

背景:心脏移植物血管病(CAV)仍然是心脏移植(HTx)受者晚期移植物衰竭和发病的主要原因。阿司匹林目前被赋予IIb类推荐用于CAV预防,这反映了支持其临床获益的证据有限。我们进行了一项系统评价和荟萃分析,以评估阿司匹林使用与HTx受者临床结局之间的关联(PROSPERO ID:CRD420261399873)。 方法:关注的结局包括全因死亡率和CAV相关临床结局(移植物功能障碍或CAV相关死亡)。文献检索截至2025年12月在PubMed和EMBASE中进行。纳入比较接受阿司匹林治疗的HTx受者与未接受阿司匹林治疗的HTx受者的研究。对各项研究中的风险比(HR)和95%置信区间(CI)进行荟萃分析。 结果:共纳入五项观察性研究,包括四个成人队列和一个儿童队列。参与者以男性为主(66.6%),四项成人研究的平均年龄约为50岁,唯一一项儿童研究的平均年龄为7.4岁。阿司匹林使用与显著较低的全因死亡率相关(四项研究,HR 0.31 [95% CI:0.15-0.67])。未观察到与CAV相关临床结局具有统计学显著关联(HR 0.42 [95% CI:0.10-1.77])。 结论:在HTx受者中,阿司匹林使用与较低的全因死亡率相关,而在CAV相关临床结局的探索性分析中未观察到显著关联。鉴于观察 观察性设计、显著异质性以及潜在的残留偏倚和时间相关偏倚。需要前瞻性研究来确定心脏移植(HTx)后阿司匹林的疗效和安全性。

完整摘要 · 英文原文

BACKGROUND: Cardiac allograft vasculopathy (CAV) remains a major cause of late graft failure and morbidity among heart transplant (HTx) recipients. Aspirin is currently assigned a Class IIb recommendation for CAV prevention, reflecting the limited evidence supporting its clinical benefit. We conducted a systematic review and meta-analysis to assess the association between aspirin use and clinical outcomes in HTx recipients (PROSPERO ID: CRD420261399873). METHODS: Outcomes of interest included all-cause mortality and CAV-related clinical outcomes (graft dysfunction or CAV-related death). Literature searches were conducted through December 2025 in PubMed and EMBASE. Studies comparing HTx recipients treated with aspirin versus no aspirin were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were meta-analyzed across studies. RESULTS: Five observational studies were included, comprising four adult cohorts and one pediatric cohort. Participants were predominantly male (66.6%), with a mean age of ≈50 years in the four adult studies and 7.4 years in the sole pediatric study. Aspirin use was associated with significantly lower all-cause mortality (four studies, HR 0.31 [95% CI: 0.15-0.67]). No statistically significant association was observed with CAV-related clinical outcomes (HR 0.42 [95% CI: 0.10-1.77]). CONCLUSIONS: In HTx recipients, aspirin use was associated with lower all-cause mortality, while no significant association was observed in the exploratory analysis of CAV-related clinical outcomes. These findings should be interpreted cautiously given the observational design, substantial heterogeneity, and potential residual and time-related biases. Prospective studies are needed to determine the efficacy and safety of aspirin after HTx.

English
Impact of Aspirin Use on Mortality and Cardiac Allograft Vasculopathy After Heart Transplantation: A Systematic Review and Meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界